Advertisement
Survey Series
Institutions
For Advertisers
|
|
||||
|
An On/Off Switch for Drug Design
Tailor-made antidotes for an aptamer-based anticoagulant reveal a new niche for these oligonucleotide drugs
Email: David Secko - dsecko@the-scientist.com The Scientist 2005, 19(6):18
|
||||
|
|
||||
|
In theory, aptamers can specifically bind and modulate the activity of any protein for which they're designed. Aptamers fold into three-dimensional structures, based on their oligonucleotide sequences, and like antibodies specifically target proteins, distinguishing them from antisense or RNA interference (RNAi). Currently, at least 23 aptamer-based therapeutic agents are under clinical development.[1]
|
|
|||||||||
|
|||||||||
|
